PMID- 32108600
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220413
IS  - 0970-2113 (Print)
IS  - 0974-598X (Electronic)
IS  - 0970-2113 (Linking)
VI  - 37
IP  - 2
DP  - 2020 Mar-Apr
TI  - Correlation of programmed death-ligand 1 expression with gene expression and 
      clinicopathological parameters in Indian patients with non-small cell lung 
      cancer.
PG  - 145-150
LID - 10.4103/lungindia.lungindia_488_19 [doi]
AB  - OBJECTIVES: The aim of this study is to evaluate the incidence of programmed cell 
      death-ligand 1 (PD-L1) expression in non-small cell lung cancer (NSCLC) cases and 
      its correlation with gene mutation and clinicopathological parameters. METHODS: 
      Samples from NSCLCs patients were studied for PD-L1 expression through 
      immunohistochemistry (IHC) using Rabbit anti-human PDL-1/CD274 Monoclonal 
      Antibody. Genetic mutations were studied using IHC/fluorescence in situ 
      hybridization (FISH) methods (for anaplastic lymphoma kinase [ALK]) or polymerase 
      chain reaction/gene sequencing analysis (for epidermal growth factor receptor 
      [EGFR]). Pearson's correlation coefficient (r) was used for correlation analysis. 
      PD-L1 expression was analyzed for association with clinicopathological features. 
      RESULTS: Of the 101 NSCLC cases, PD-L1 expression was observed in 33.66% (34/101) 
      cases; tumor proportion score of <50%: 67.65% (23/34) and >/=50%: 32.35% (11/34) 
      cases. PD-L1 positivity was seen in; males: 35.5%, females: 28%, smokers: 37.7%, 
      cases with brain metastasis: 20%, cases with pleural effusion: 20.8%, and 
      histopathological evaluation (well-differentiated: 21.42%, 
      moderately-differentiated: 13.79%, poorly-differentiated: 36.11%, and 
      adenosquamous disease: 40.9%). Genetic mutation studies revealed PD-L1 positivity 
      in 18.1% cases with EGFR mutation, 50% of ALK-IHC positive cases, and 33.3% 
      ALK-FISH positive cases. No or very weak correlation (r < 0.3) in PD-L1 
      expression with gene mutations or clinicopathological parameters was observed. 
      CONCLUSIONS: The study demonstrated PD-L1 expression in ~ 1/3(rd) cases of NSCLC 
      patients. No or very weak correlation was observed for PD-L1 expression with 
      genetic mutations and other parameters studied. The presence of gene mutations in 
      PD-L1 expressed samples suggests further investigation on PD-L1 inhibitors in 
      such patients for decisive treatments.
FAU - Kumar, Manish
AU  - Kumar M
AD  - Department of Medical Oncology, Army Hospital Research and Referral, New Delhi, 
      India.
FAU - Guleria, Bhupesh
AU  - Guleria B
AD  - Department of Medical Oncology, Army Hospital Research and Referral, New Delhi, 
      India.
FAU - Swamy, Shivashankar
AU  - Swamy S
AD  - Department of Medical Oncology, Army Hospital Research and Referral, New Delhi, 
      India.
FAU - Soni, Sneha
AU  - Soni S
AD  - Assistant Professor, Community Medicine, Rama Medical College, Hapur, Uttar 
      Pradesh, India.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Lung India
JT  - Lung India : official organ of Indian Chest Society
JID - 8405380
PMC - PMC7065552
OTO - NOTNLM
OT  - Anaplastic lymphoma kinase
OT  - clinicopathological
OT  - epidermal growth factor receptor
OT  - non-small cell lung cancer
OT  - programmed cell death-ligand 1
COIS- None
EDAT- 2020/02/29 06:00
MHDA- 2020/02/29 06:01
PMCR- 2020/03/01
CRDT- 2020/02/29 06:00
PHST- 2020/02/29 06:00 [entrez]
PHST- 2020/02/29 06:00 [pubmed]
PHST- 2020/02/29 06:01 [medline]
PHST- 2020/03/01 00:00 [pmc-release]
AID - LungIndia_2020_37_2_145_279584 [pii]
AID - LI-37-145 [pii]
AID - 10.4103/lungindia.lungindia_488_19 [doi]
PST - ppublish
SO  - Lung India. 2020 Mar-Apr;37(2):145-150. doi: 10.4103/lungindia.lungindia_488_19.